MZP News
Home Companies Cronos Group Inc. News: Why CRON Stock Is Zooming Higher Today
Cronos Group Inc. News: Why CRON Stock Is Zooming Higher Today
Kevin Freeman
Cronos Group Inc. [CRON] has traded in a range of $4.00 to $9.15 in the last 1 year. As of this writing, the stock is at $8.65, up 3.97%. To check whether the stock's short-term amount has a thrust, its good to check stock's recent movement. Over the last week, CRON shares are 13.35% up with the monthly amount drift of 57.28% and seems well in a long time frame.
On 25, November 2020, Cronos Group Inc. to Speak at the Cowen 2020 Boston Cannabis Conference. According to news published on Yahoo Finance, Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos Group" or the "Company"), an innovative global cannabinoid company, today announced that Mike Gorenstein, Executive Chairman, is scheduled to speak on a panel at the Cowen 2020 Boston Cannabis Conference on Wednesday, December 2, 2020 at 9:20 a.m. EST.
Analyst Birdseye View:
The most recent analyst activity for Cronos Group Inc. [NASDAQ:CRON] stock was on April 27, 2020, when it was Downgrade with a Mkt perform rating from Raymond James. On April 14, 2020, Piper Sandler Downgrade a Neutral rating. On April 02, 2020, BofA/Merrill Downgrade a Neutral rating. On March 31, 2020, Canaccord Genuity Downgrade a Sell rating. On March 04, 2020, MKM Partners Upgrade a Buy rating. On March 03, 2020, Stifel Downgrade a Hold rating.
In the past 52 weeks of trading, this stock has oscillated between a low of $4.00 and a peak of $9.15. Right now, according to Wall Street analyst the average 12-month amount target is $6.24. At the most recent market close, shares of Cronos Group Inc. [NASDAQ:CRON] were valued at $8.65.
Cronos Group Inc. [NASDAQ:CRON] most recently reported quarterly sales of 15.13 billion, which represented growth of 96.30%. This publicly-traded organization's revenue is $49,785 per employee, while its income is $2,445,235 per employee. Continuing to look at profitability, this corporation's Return on Assets, Equity, Whole Principal & invested Principal is sitting at 103.97, 124.79, -12.28 and 124.36 respectively.
If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 0.40 and the whole liability to whole assets at 0.34. It shows enduring liability to the whole principal at 0.38 and enduring liability to assets at 0.00 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company's stock is sitting at 7.99 points at 1st support level, the second support level is making up to 7.66. But as of 1st resistance point, this stock is sitting at 8.90 and at 9.48 for 2nd resistance point.
Important Ratio's To Watch
Quick ratio, showing Cash ratio at 4.52. Now if looking for a valuation of this stock's amount to sales ratio it's 108.46, it's amount to book ratio is 1.53 and showing 28.99 of P/E (TTM) ratio.
The most recent insider trade was by ADLER JASON MARC, Director, and it was the sale of 100000.0 shares on Nov 17. ADLER JASON MARC, the Director, completed a sale of 9300.0 shares on Nov 11. On Nov 10, ADLER JASON MARC, Director, completed a sale of 21361.0 shares.
CRON stock
NASDAQ:CRON
Previous articleDon't Be Fooled By Gain in Infosys Limited [INFY] Stock
Next articleIt's Time to Buy the lift in Avinger Inc. [AVGR] Stock
Illinois [NYSE: ITW] Inked A Contract To Purchase MTS's Testing & Stimulation Business From Amphenol
CDC Awards Quest Diagnostic [NYSE: DGX] Agreement To Provide The Genomic Sequence Of SARS-CoV-2 Virus.
Why Today Is the Best Time to Buy Penn National Gaming Inc. [PENN] Stock at $79.01
© MZP News. All rights reserved.
Illinois [NYSE: ITW] Inked A Contract To Purchase MTS's Testing &...
Lockheed [NYSE: LMT] Secures A Foreign Military Sales Contract Worth $254.7M...
CDC Awards Quest Diagnostic [NYSE: DGX] Agreement To Provide The Genomic...